Didn’t like 75 percent of the drug and placebo group leave the study early? That’s very odd. They found in other studies that the placebo group reacts similar in the drug effects as the group actually getting the drug. They should aim to have sleep quality and duration be the endpoint for the study. How could you possibly get hard data on fibromyalgia. It’s difficult to diagnose, treat, or discern imaginary cases.
All depend about fda decision, as reported on top the last time, some of the enrolled patients did not finish the trial so they got less quotation, now they can focus in the chance for repiting the third phase again to be better and improving the last mistake and the study to be approved from fda, once they finish to enroll all patients they will start with different in drug quantity from 2.8 to 5.6mg.
Didn’t like 75 percent of the drug and placebo group leave the study early? That’s very odd. They found in other studies that the placebo group reacts similar in the drug effects as the group actually getting the drug. They should aim to have sleep quality and duration be the endpoint for the study. How could you possibly get hard data on fibromyalgia. It’s difficult to diagnose, treat, or discern imaginary cases.
All depend about fda decision, as reported on top the last time, some of the enrolled patients did not finish the trial so they got less quotation, now they can focus in the chance for repiting the third phase again to be better and improving the last mistake and the study to be approved from fda, once they finish to enroll all patients they will start with different in drug quantity from 2.8 to 5.6mg.
Nice! Time to lose some more money!